Iovance Biotherapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IOVA research report →
Range $5 – $20
Price Chart
About the company
Iovance Biotherapeutics, Inc. , a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells.
- CEO
- Frederick G. Vogt
- IPO
- 2010
- Employees
- 975
- HQ
- San Carlos, CA, US
Get TickerSpark's AI analysis on IOVA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $3.38B
- P/E
- -13.79
- Fwd P/E
- 26.51
- PEG
- -0.15
- P/S
- 8.92
- P/B
- 4.10
- EV/EBITDA
- -18.20
- Div Yield
- 0.00%
- Gross Margin
- 53.23%
- Op Margin
- -60.79%
- Net Margin
- -58.19%
- ROE
- -29.71%
- ROIC
- -25.80%
Latest fiscal year · YoY change
- Revenue
- $263.50M+60.6%
- Gross Profit
- $90.32M+125.4%
- Op Income
- $-398,213,000
- Net Income
- $-390,978,000-5.1%
- EPS
- $-1.09+14.8%
- OCF Growth
- +14.3%
- FCF Growth
- +7.6%
- Beta
- 0.76
- RSI (14)
- 29
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Iovance posted a record third quarter with about $122 million in revenue, 60% gross margin, and continued commercial momentum for AMTAGVI, while advancing lung, sarcoma, and melanoma pipeline programs.· November 5, 2026
- Total revenue was about $122 million, up 80% year over year and 22% sequentially, with AMTAGVI sales around $102 million, up 77% year over year.
- Gross margin reached about 60%, a new high for the second straight quarter, while R&D spend fell about 16% sequentially to about $49 million and SG&A held flat at about $39 million.
- Management reaffirmed full-year revenue guidance of $410 million-$420 million and said the company still expects to reach 110 or more ATCs by year-end.
- The company said more than 1,000 commercial AMTAGVI patients have now been infused in the U.S. since launch, and community ATCs are becoming a larger part of the network.
- Pipeline updates included positive updated IOV-LUN-202 data in non-squamous NSCLC, new biomarker-enriched precision TIL plans, and updated sarcoma and melanoma data from ESMO.
Iovance reported third-quarter total revenue of about $122 million, up 80% year over year and 22% sequentially. AMTAGVI revenue was around $102 million, up 77% year over year and 12% sequentially, while Proleukin revenue was approximately $20 million, more than double the second quarter level. Gross margin was about 60%, up from the prior record of 56%, and year-to-date margin was 54%. On profitability, management cited a quarterly operating loss of approximately $24 million and EPS loss of $0.05. Cash equivalents, short-term investments, and restricted cash were approximately $382 million at September 30. The company reaffirmed full-year revenue guidance of $410 million-$420 million and said it expects to reach 110 or more authorized treatment centers by year-end; it also said the cash runway should fund operations well into 2029.
Fred Vogt called the quarter record-setting and emphasized that commercial execution, margin expansion, and pipeline progress were all moving together. He highlighted more than 1,000 infused commercial AMTAGVI patients in the U.S., rapid ATC expansion, and the view that cash runway now extends well into 2029. On the pipeline, he stressed that the company is preparing for a 2027 sBLA in non-squamous NSCLC and is pursuing biomarker-enriched and additional frontline opportunities alongside broader sarcoma and melanoma development.
Corleen Roche said the quarter combined strong revenue, record margin, and disciplined spending. She pointed to about $122 million in revenue, AMTAGVI sales of around $102 million, Proleukin revenue of approximately $20 million, and gross-to-net deductions of around 1%. She also noted R&D fell about 16% sequentially to about $49 million, SG&A held at about $39 million, and cash ended at approximately $382 million, supporting a runway into 2029. She reaffirmed the full-year revenue guide of $410 million-$420 million and said capital allocation remains focused on the highest-return priorities.
Analysts focused on near-term commercial trends, profitability, Proleukin timing, ATC mix, and regulatory plans for lung cancer. Management said the seasonal maintenance issue that previously affected first-quarter earnings is no longer a factor, and Fred Vogt said they expect quarter-over-quarter growth in Q4 but are primarily tracking to the recently issued guidance. On profitability, Corleen Roche said the company is “on our way to profitability” and pointed to the $0.05 EPS loss as the best result to date. In the Q&A on IOV-LUN-202, management said FDA discussions are productive, they believe the dataset should be registrational, and they still plan a BLA submission in 2027 with about 80 subjects.
The bull case from this call is that commercial adoption is still accelerating, with AMTAGVI topping $100 million in quarterly sales for the first time and the ATC network expanding to more than 100 sites. Management also signaled continued margin improvement, a cash runway into 2029, and multiple pipeline shots on goal, including a planned 2027 sBLA in NSCLC and new biomarker-enriched development paths.
The main risks are that the company is still not profitable and is relying on continued execution to sustain growth and margin gains. Pipeline value is still largely ahead of it, with major regulatory submissions not expected until 2027 or later, and management acknowledged that some durability data may remain immature. Commercial growth also depends on maintaining demand, scaling community ATCs, and continuing to align wholesaler ordering and treatment timing.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 87.0%
- Shares Outstanding
- 462.65M
- Float Shares
- 402.69M
of shares held by institutions
305 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 37.90M | ▲ 946.28K |
| Mhr Fund Management LLC | 28.97M | 0 |
| Vanguard Group Inc | 27.21M | ▲ 3.15M |
| State Street Corp | 21.70M | ▼ 2.78M |
| Two Sigma Investments, LP | 19.01M | ▲ 5.32M |
| Vanguard Capital Management LLC | 18.40M | ▲ 192.46K |
| Vanguard Portfolio Management LLC | 12.28M | ▼ 2.11M |
| Geode Capital Management, LLC | 10.45M | ▲ 127.42K |
| Millennium Management LLC | 8.53M | ▼ 888.37K |
| Dimensional Fund Advisors LP | 6.24M | ▼ 221.76K |
| Palo Alto Investors LP | 5.30M | ▼ 1.05M |
| Goldman Sachs Group Inc | 5.10M | ▼ 3.66M |
Held by 327 ETFs
Biggest fund positions in IOVA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 11, 26 | Vogt Frederick G | other | 200,000 |
| Nov 11, 26 | Vogt Frederick G | other | 191,303 |
| Nov 11, 26 | Vogt Frederick G | other | 200,000 |
| Nov 10, 26 | Kirby Daniel Gordon | other | 10,000 |
| Nov 10, 26 | Kirby Daniel Gordon | other | 3,935 |
| Nov 10, 26 | Kirby Daniel Gordon | other | 10,000 |
| Nov 6, 26 | Roche Corleen M. | other | 12,500 |
| Nov 6, 26 | Roche Corleen M. | other | 12,500 |
| Nov 6, 26 | Roche Corleen M. | other | 5,311 |
| Sep 30, 26 | Berkowitz Noah | other | 180,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IOVA coverage
Recent articles, reports, and earnings notes.

Should You Buy the Electra Therapeutics IPO? Here's the Setup
Electra Therapeutics is expected to list on NASDAQ on 2026-09-18 in a $14.00 to $16.00 range. The company is offering 21,666,667 shares under ticker ETRA. The bull case is a first-in-class immune-cell depletion platform; the bear case is a clinical-stage biotech with no revenue and rising losses.

Inside the Obsidian Therapeutics IPO: Reverse-Merger Setup, Risks, and Watchpoints
Obsidian Therapeutics, Inc. Common Stock (NASDAQ: OBX) is expected to list on 2026-08-04, but the price range has not been disclosed. The company is coming to market through an all-stock reverse merger with Galera Therapeutics rather than a traditional IPO. Bull case: a differentiated cell-therapy platform with strong strategic backing; bear case: no disclosed pricing, no commercial revenue, and heavy clinical risk.

What to Watch as SL Science Holding Limited Prices on Nasdaq
SL Science Holding Limited Ordinary Shares (SLBT) is expected to list on Nasdaq on 2026-06-15, but the price range has not been disclosed. This is a de-SPAC listing rather than a traditional IPO, so the key question is whether the market gives credit to a small-revenue biotech platform with a very large headline valuation.
Want a deeper read on IOVA?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.